NDA 016267 · Mitem Pharma
Desferal
Deferoxamine Mesylate · Injection
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Sep 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1968
Apr 1, 1968
Approved uses
2
Original approval plus efficacy supplements
Registered trials
70
14 Phase 3, 8 recruiting
FAERS reports
1,676
1,487 serious, 334 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 2, 2025.
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 4, 1979 Supplement 11 · Efficacy
- Apr 1, 1968 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- DESFERAL · DEFEROXAMINE MESYLATE 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- DESFERAL · DEFEROXAMINE MESYLATE 500MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Deferoxamine" as an intervention, any sponsor and status, largest first.
- ACT-GLOBAL Adaptive Platform Trial for StrokePivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06352632 · 20,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 2034
Drug: Standard-dose intravenous tenecteplase; Low-dose intravenous tenecteplase and 9 more · For: Stroke
Sites: Sydney, Australia; Calgary, Canada
- The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBALPivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06763055 · 2,000 participants (planned) · Start Feb 27, 2025 · Primary completion Jan 2028
Drug: Colchicine 0.5 mg; Deferoxamine Mesylate · For: Intracerebral Hemorrhage; Spontaneous Intracerebral Hemorrhage; Supratentorial Intracerebral Haemorrhage and 2 more
Sites: Sydney, Australia; Chengdu, China
- Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00061750 · 595 participants · Start May 2003 · Primary completion Nov 2004
Drug: ICL670; deferoxamine · For: Beta-Thalassemia
Sites: Los Angeles, California; Oakland, California; Stanford, California · 7 sites in all
- Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major ThalassemiaPivotal-lookingCompleted
Beni-Suef UniversityAcademic, hospital or other
NCT04292314 · 350 participants · Start Nov 1, 2019 · Primary completion Dec 20, 2020
Drug: Omega 3; Nigella Sativa Oil and 3 more · For: Iron Overload; Oxidative Stress; Thalassemia Major
Sites: Banī Suwayf, Egypt; Mecca, Saudi Arabia · 4 sites in all
- Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney InjuryPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT04633889 · 320 participants · Start Apr 13, 2021 · Primary completion Aug 26, 2024
Drug: Deferoxamine; Normal saline · For: Acute Kidney Injury
Sites: Boston, Massachusetts · 3 sites in all
- Intracerebral Hemorrhage Deferoxamine Trial - iDEF TtrialPivotal-lookingCompleted
Beth Israel Deaconess Medical CenterAcademic, hospital or other
NCT02175225 · 294 participants · Start Oct 2014 · Primary completion Feb 10, 2018
Drug: Deferoxamine Mesylate; Placebo (for Deferoxamine Mesylate) · For: Intracerebral Hemorrhage
Sites: Phoenix, Arizona; Palo Alto, California; San Francisco, California · 28 sites in all
- Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in TunisiaPivotal-lookingStatus unknown
Abderrahmane Mami HospitalAcademic, hospital or other
NCT04361032 · 260 participants (planned) · Start Sep 4, 2020 · Primary completion Sep 4, 2020
Drug: Tocilizumab Injection; Deferoxamine · For: COVID19; Intensive Care Unit
Sites: Aryanah, Tunisia
- A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00171171 · 252 participants · Start May 2004 · Primary completion Nov 2006
Drug: deferasirox · For: Beta-Thalassemia; Hemosiderosis
Sites: Cairo, Egypt; Beirut, Lebanon; Muscat, Oman · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- serum ferritin increased157
- pyrexia116
- diarrhoea105
- haemoglobin decreased101
- off label use100
- vomiting90
- nausea87
- death85
- fatigue76
- drug ineffective75
- dyspnoea73
- blood creatinine increased71
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 26 |
| 2005 | 27 |
| 2006 | 61 |
| 2007 | 49 |
| 2008 | 70 |
| 2009 | 86 |
| 2010 | 75 |
| 2011 | 102 |
| 2012 | 128 |
| 2013 | 63 |
| 2014 | 98 |
| 2015 | 95 |
| 2016 | 111 |
| 2017 | 114 |
| 2018 | 77 |
| 2019 | 74 |
| 2020 | 66 |
| 2021 | 34 |
| 2022 | 81 |
| 2023 | 62 |
| 2024 | 67 |
| 2025 | 60 |
| 2026 | 49 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Iron chelators for acute stroke.
Van der Loo LE, Aquarius R, Teernstra O, et al. · Cochrane Database Syst Rev 2020 · Systematic Review
- Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
Tendler S, Dunphy MP, Agee M, et al. · Lancet Oncol 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Deferoxamine in intracerebral hemorrhage: Systematic review and meta-analysis.
Sun T, Zhao YY, Xiao QX, et al. · Clin Neurol Neurosurg 2023 · Meta-Analysis, Systematic Review
- Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Meerpohl JJ, Schell LK, Rücker G, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Deferoxamine for advanced hepatocellular carcinoma.
Yamasaki T, Terai S, Sakaida I · N Engl J Med 2011 · Clinical Trial, Letter
- Predicting Gastrostomy Tube Placement After Intracerebral Hemorrhage: External Validation of the GRAVo Score.
Lin D, Minyetty M, Selim M, et al. · Neurocrit Care 2022 · Multicenter Study, Randomized Controlled Trial
Sponsor: Mitem Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.